Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Fasturtec
Active Ingredient: Rasburicase 1.5mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Sanofi-Synthelabo (NZ) Limited
Manufacturer: Sanofi Winthrop Industrie, Notre Dame de Bondeville, France
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 24th day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).